Literature DB >> 15909994

5' transcript replacement in vitro catalyzed by a group I intron-derived ribozyme.

Rashada C Alexander1, Dana A Baum, Stephen M Testa.   

Abstract

Group I intron-derived ribozymes can perform a variety of catalytic reactions, including the replacement of the 3' end of a mutant RNA transcript with a corrected version of the transcript [Sullenger, B. A., and Cech, T. R. (1994) Nature 371, 619-622]. We now demonstrate in vitro that a ribozyme, derived from a Pneumocystis carinii group I intron, can replace the 5' end of a targeted exogenous RNA with an endogenous RNA. Our model system is a short synthetic mimic of a k-ras transcript, in which substitution mutations at codon 12 are implicated in a host of cancer types. In these experiments, yields of up to 70% were obtained. We analyzed the length dependence of two molecular contacts, P9.0 and P10, that occur between the ribozyme and the exogenous k-ras mimic, and determined that longer, and thus more stable, interactions result in higher product yields. Furthermore, the length of the loop region L1 can substantially influence the yield and the rate of the reaction. These results are a further demonstration that group I intron-derived ribozymes are quite malleable in terms of intermolecular recognition and catalysis, and that these properties can be exploited in developing potentially useful biochemical tools.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909994     DOI: 10.1021/bi047284a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Engineering a family of synthetic splicing ribozymes.

Authors:  Austin J Che; Thomas F Knight
Journal:  Nucleic Acids Res       Date:  2010-03-18       Impact factor: 16.971

2.  Site-Selective RNA Splicing Nanozyme: DNAzyme and RtcB Conjugates on a Gold Nanoparticle.

Authors:  Jessica R Petree; Kevin Yehl; Kornelia Galior; Roxanne Glazier; Brendan Deal; Khalid Salaita
Journal:  ACS Chem Biol       Date:  2017-12-19       Impact factor: 5.100

3.  Increased efficiency of evolved group I intron spliceozymes by decreased side product formation.

Authors:  Zhaleh N Amini; Ulrich F Müller
Journal:  RNA       Date:  2015-06-23       Impact factor: 4.942

Review 4.  Mutation-Directed Therapeutics for Neurofibromatosis Type I.

Authors:  Andre Leier; David M Bedwell; Ann T Chen; George Dickson; Kim M Keeling; Robert A Kesterson; Bruce R Korf; Tatiana T Marquez Lago; Ulrich F Müller; Linda Popplewell; Jiangbing Zhou; Deeann Wallis
Journal:  Mol Ther Nucleic Acids       Date:  2020-04-29       Impact factor: 8.886

Review 5.  Design and Experimental Evolution of trans-Splicing Group I Intron Ribozymes.

Authors:  Ulrich F Müller
Journal:  Molecules       Date:  2017-01-02       Impact factor: 4.411

6.  Trans-splicing with the group I intron ribozyme from Azoarcus.

Authors:  Gregory F Dolan; Ulrich F Müller
Journal:  RNA       Date:  2013-12-16       Impact factor: 4.942

7.  Spliceozymes: ribozymes that remove introns from pre-mRNAs in trans.

Authors:  Zhaleh N Amini; Karen E Olson; Ulrich F Müller
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.